Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
about
Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospectsAssociation between metabolic factors and chronic hepatitis B virus infection.Synergistic interaction between genetics and disease on pravastatin dispositionNonalcoholic fatty liver disease and cardiovascular diseasePerilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte.Role of diet and lifestyle changes in nonalcoholic fatty liver diseaseThe hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.CIDEC/FSP27 is regulated by peroxisome proliferator-activated receptor alpha and plays a critical role in fasting- and diet-induced hepatosteatosis.NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapyKASL clinical practice guidelines: management of nonalcoholic fatty liver disease.Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review.Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition.Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools.Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease.Effects of rhaponticum carthamoides versus glycyrrhiza glabra and punica granatum extracts on metabolic syndrome signs in rats.Opposite association between diabetes, dyslipidemia, and hepatocellular carcinoma mortality in the middle-aged and elderly.Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins.Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice.
P2860
Q26828615-8C9D2CEF-AC84-4633-A880-568D93CD4FFCQ33780113-9FDC89B9-25F8-43EF-8835-052507972444Q33786577-71EBD645-C208-4D20-818C-97479B2FB2FEQ33886952-5BC34E05-B04F-4841-A468-5503B66480C0Q33923114-DC575427-E3C0-43E5-88AD-A8906EFEEFCEQ33948329-F7F41EA5-AC58-449C-8ECE-7B79C5B2ECBBQ34303169-D538273F-928C-4952-9BD3-24DB2933903BQ34647400-96B7BFE2-663F-43F9-BA25-E6227B495133Q35224351-E048932A-A794-42D2-9AD7-514A95FDC7D6Q36654473-432E0559-3512-411D-BB44-321DBF4A3D0FQ37115301-3EE7A7B9-5D36-4136-8B4D-52AEC528636DQ37488800-C2BC6A5C-5288-4C87-88F3-7E6BD24B796FQ37603899-E216FD6E-2E53-404F-8D7C-338EDE5D3EA5Q38074826-09F1B490-CD44-4219-8BC8-DF108187854FQ38195808-DF83E716-914B-4D39-B763-E25822054173Q38209324-5135E024-3BFC-4B67-A7CC-17C602B41073Q38845683-6B19B5D8-8035-46CB-B651-7EC92DF60FE9Q39213226-57A5F9A3-8DC3-4054-830C-3692EDD0AE10Q39272331-792758C8-9912-4F04-9FE0-266F017D11E1Q47104903-BAF30ECF-B3EA-4150-97E5-863A9829FDBBQ47271581-650FD64A-BD88-40FE-AF69-AB35998EEE50Q47718804-6A86E73A-6878-4E7F-8169-918BF22A45B2
P2860
Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lipid-lowering agents in nonal ...... teatohepatitis: human studies.
@en
Lipid-lowering agents in nonal ...... teatohepatitis: human studies.
@nl
type
label
Lipid-lowering agents in nonal ...... teatohepatitis: human studies.
@en
Lipid-lowering agents in nonal ...... teatohepatitis: human studies.
@nl
prefLabel
Lipid-lowering agents in nonal ...... teatohepatitis: human studies.
@en
Lipid-lowering agents in nonal ...... teatohepatitis: human studies.
@nl
P2093
P2860
P1476
Lipid-lowering agents in nonal ...... teatohepatitis: human studies.
@en
P2093
Julnar Mograbi
Murad Ghali
William Nseir
P2860
P2888
P304
P356
10.1007/S10620-012-2118-3
P577
2012-03-15T00:00:00Z